Boston Scientific, Nevro settle ongoing intellectual property litigations
This settlement concludes all of the existing litigations between Nevro and Boston Scientific, and includes a net payment from Boston Scientific to Nevro of $85 million.
Redwood City: Nevro Corp. and Boston Scientific Corp. announced that they have reached a settlement in their ongoing intellectual property litigations that gives Boston Scientific the freedom to operate using the features and capabilities embodied in its current line of products for frequencies below 1,500 Hz, and gives Nevro the freedom to operate using the features and capabilities embodied in its current line of products.
Nevro will grant Boston Scientific a worldwide, non-exclusive, non-transferable license to practice paresthesia-free therapy at frequencies below 1,500 Hz and a covenant not to sue for any features embodied in any current Boston Scientific products for frequencies below 1,500 Hz.
Boston Scientific also will grant Nevro a worldwide, non-exclusive, non-transferable license under Boston Scientific's asserted patent families and a covenant not to sue for any features embodied in any current Nevro products.
This settlement concludes all of the existing litigations between Nevro and Boston Scientific, and includes a net payment from Boston Scientific to Nevro of $85 million.
Read also: Boston Scientific to buy Baylis Medical for USD 1.75 billion: Bloomberg
Headquartered in Redwood City, California, Nevro is a global medical device company. Nevro's comprehensive HFX spinal cord stimulation (SCS) platform includes a Senza SCS system and support services for the treatment of chronic trunk and limb pain and painful diabetic neuropathy. Senza, Senza II, and Senza Omnia are the SCS systems that deliver Nevro's proprietary 10 kHz Therapy.
Read also: Boston Scientific Corp releases quarterly results, says elective surgery recover in July
